azomycin has been researched along with ku 2285 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (89.47) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Oya, N; Sasai, K; Shibamoto, Y; Streffer, C | 1 |
| Abe, M; Iwai, H; Kitakabu, Y; Nishimoto, S; Oya, N; Sasai, K; Shibamoto, Y; Takahashi, M; Yoshizawa, T | 1 |
| Hisanaga, Y; Kagiya, T; Kitakabu, Y; Nishimoto, S; Sasai, K; Shibamoto, Y; Shimokawa, K; Takahashi, M; Wang, J; Zhou, L | 1 |
| Abe, M; Fushiki, M; Iwai, H; Nishimoto, S; Sasai, K; Shibamoto, Y; Suyama, S; Takahashi, M; Yukawa, Y | 1 |
| Abe, M; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Sugiyama, T | 1 |
| Streffer, C; Tamulevicius, P | 1 |
| Abe, M; Iwai, H; Nishimoto, S; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Yoshizawa, T | 1 |
| Abe, M; Kitakabu, Y; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takahashi, M | 1 |
| Abe, M; Ishigaki, T; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T | 1 |
| Abe, M; Iwai, H; Matsuno, E; Sasai, K; Shibamoto, Y | 1 |
| Abe, M; Iwai, H; Murata, R; Oya, N; Shibamoto, Y; Shibata, T; Sugiyama, T | 1 |
| Abe, M; Oya, N; Sasai, K; Shibamoto, Y; Sugiyama, T | 1 |
| Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T | 1 |
| Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T; Takahashi, M | 1 |
| Abe, M; Shibamoto, Y; Takahashi, M | 1 |
| Akuta, K; Kinashi, Y; Masunaga, S; Ono, K; Suzuki, M | 1 |
| Abe, M; Hosotani, R; Imamura, M; Manabe, T; Nishimura, Y; Ohshio, G; Shibamoto, Y | 1 |
| Ito, M; Ogino, H; Shibamoto, Y; Sugie, C | 1 |
| Hori, H; Ito, M; Nagasawa, H; Ogino, H; Shibamoto, Y; Sugie, C; Suzuki, H; Uto, Y | 1 |
1 review(s) available for azomycin and ku 2285
| Article | Year |
|---|---|
The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Topics: Asian People; Cell Hypoxia; Clinical Trials as Topic; Humans; Imidazoles; Neoplasms; Nitroimidazoles; Prodrugs; Radiation; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 2004 |
2 trial(s) available for azomycin and ku 2285
| Article | Year |
|---|---|
A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy.
Topics: Administration, Oral; Adult; Aged; Cell Hypoxia; Female; Humans; Male; Middle Aged; Nitroimidazoles; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1996 |
A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Combined Modality Therapy; Female; Humans; Intraoperative Care; Male; Middle Aged; Nitroimidazoles; Osteosarcoma; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 1997 |
16 other study(ies) available for azomycin and ku 2285
| Article | Year |
|---|---|
Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay.
Topics: Animals; Cell Hypoxia; Dose-Response Relationship, Drug; Etanidazole; Mice; Micronucleus Tests; Nitroimidazoles; Nucleosides; Radiation Dosage; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1992 |
Pharmacokinetics of fluorinated 2-nitroimidazole hypoxic cell radiosensitizers in murine peripheral nervous tissue.
Topics: Animals; Cell Hypoxia; Etanidazole; Female; Half-Life; Mice; Mice, Inbred C3H; Nitroimidazoles; Peripheral Nerves; Radiation-Sensitizing Agents | 1992 |
A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
Topics: Animals; Combined Modality Therapy; Dose-Response Relationship, Radiation; Etanidazole; Female; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Radiation-Sensitizing Agents | 1991 |
In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.
Topics: Animals; Carcinoma, Squamous Cell; Cell Survival; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1991 |
Combined cytokinesis-block micronucleus and chromosomal aberration assay for the evaluation of radiosensitizers at low radiation doses.
Topics: Aerobiosis; Animals; Cell Line; Chromosome Aberrations; Dose-Response Relationship, Radiation; Etanidazole; Female; Mice; Mice, Inbred BALB C; Micronucleus Tests; Mutagenicity Tests; Neoplasms, Experimental; Nitroimidazoles; Radiation-Sensitizing Agents | 1994 |
Metabolic studies and neurotoxicity in tumors and brain of mice after hypoxic cell sensitizers.
Topics: Adenosine Triphosphate; Animals; Brain; Etanidazole; Glucose; Male; Mice; Mice, Inbred C57BL; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Nucleosides; Radiation-Sensitizing Agents | 1994 |
Fluorinated 2-nitroimidazole derivative hypoxic cell radiosensitizers: radiosensitizing activities and pharmacokinetics.
Topics: Animals; Female; Mice; Mice, Inbred C3H; Nitroimidazoles; Radiation-Sensitizing Agents; Solubility | 1994 |
Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Mice; Mice, Inbred C3H; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1994 |
Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses.
Topics: Animals; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship, Drug; Etanidazole; Female; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents | 1994 |
Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice.
Topics: Animals; Carcinoma, Squamous Cell; Etanidazole; Female; Male; Mice; Mice, Inbred C3H; Mice, Inbred ICR; Misonidazole; Nitroimidazoles; Peripheral Nerves; Radiation-Sensitizing Agents | 1994 |
KIN-804 vs. KU-2285 as a radiosensitizer for clinical use.
Topics: Animals; Carcinoma, Squamous Cell; Chromosome Aberrations; Female; Humans; Hydroxamic Acids; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents | 1994 |
In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses.
Topics: Animals; Cell Division; Cell Line; Chromosome Aberrations; Dose-Response Relationship, Radiation; Etanidazole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Micronucleus Tests; Nitroimidazoles; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 1993 |
Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasms, Experimental; Nitroimidazoles; Radiotherapy Dosage; Tirapazamine; Triazines | 1996 |
Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Dose-Response Relationship, Radiation; Humans; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Nitroimidazoles; Radiation-Sensitizing Agents; Tirapazamine; Triazines; Tumor Cells, Cultured | 1996 |
The radiosensitizing effects of hypoxic cell sensitizer on SCCVII tumors in mice evaluated by highly accurate colony formation assay assisted by microcomputer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Etanidazole; Male; Mice; Mice, Inbred C3H; Microcomputers; Misonidazole; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; Mice; Nimorazole; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Outcome; Triazoles | 2005 |